MX394899B - Forma solida de (s)-[2-cloro-4-fluoro-5-(7-morfolin-4-il-quinazolin-4-il)fenil]-(6-metoxi-piridazin-3-il)-metanol. - Google Patents

Forma solida de (s)-[2-cloro-4-fluoro-5-(7-morfolin-4-il-quinazolin-4-il)fenil]-(6-metoxi-piridazin-3-il)-metanol.

Info

Publication number
MX394899B
MX394899B MX2019011649A MX2019011649A MX394899B MX 394899 B MX394899 B MX 394899B MX 2019011649 A MX2019011649 A MX 2019011649A MX 2019011649 A MX2019011649 A MX 2019011649A MX 394899 B MX394899 B MX 394899B
Authority
MX
Mexico
Prior art keywords
ylquinazolin
pyridazin
morpholin
fluoro
chloro
Prior art date
Application number
MX2019011649A
Other languages
English (en)
Other versions
MX2019011649A (es
Inventor
Clemens Kuehn
David Maillard
Edoardo Burini
Marcel Breuning
Marco Poma
Michael Lange
Thomas Fuchss
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2019011649A publication Critical patent/MX2019011649A/es
Publication of MX394899B publication Critical patent/MX394899B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • B01D9/0054—Use of anti-solvent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a (S)-[2-cloro-4-fluoro-5-(7-morfolin-4-ilquinazolin-4-il)fenil]-(6-metoxi-piridazin-3-il)-metanol cristalino desordenado anhidro, así como un método para producir el mismo, y composiciones farmacéuticas y usos médicos del mismo.
MX2019011649A 2017-03-30 2018-03-28 Forma solida de (s)-[2-cloro-4-fluoro-5-(7-morfolin-4-il-quinazolin-4-il)fenil]-(6-metoxi-piridazin-3-il)-metanol. MX394899B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17163826 2017-03-30
PCT/EP2018/057875 WO2018178133A1 (en) 2017-03-30 2018-03-28 Solid form of (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol

Publications (2)

Publication Number Publication Date
MX2019011649A MX2019011649A (es) 2019-12-19
MX394899B true MX394899B (es) 2025-03-24

Family

ID=58461171

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011649A MX394899B (es) 2017-03-30 2018-03-28 Forma solida de (s)-[2-cloro-4-fluoro-5-(7-morfolin-4-il-quinazolin-4-il)fenil]-(6-metoxi-piridazin-3-il)-metanol.

Country Status (16)

Country Link
US (1) US11053233B2 (es)
EP (1) EP3601265B1 (es)
JP (1) JP7365904B2 (es)
KR (1) KR20190136037A (es)
CN (1) CN110446705B (es)
AU (1) AU2018246257B2 (es)
CA (1) CA3058285C (es)
DK (1) DK3601265T3 (es)
ES (1) ES2956036T3 (es)
IL (1) IL269667B2 (es)
MX (1) MX394899B (es)
RU (1) RU2019133577A (es)
SG (1) SG11201909059XA (es)
TW (1) TWI781161B (es)
WO (1) WO2018178133A1 (es)
ZA (1) ZA201907144B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102013008118A1 (de) * 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
US11103512B2 (en) * 2017-03-30 2021-08-31 Merck Patent Gmbh Crystalline form of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)-methanol
EP3992189A4 (en) 2019-06-27 2022-12-07 Medshine Discovery Inc. QUINAZOLINE AND CINNOLINE DERIVATIVES AS DNA PK INHIBITORS
CN116670128A (zh) * 2020-12-28 2023-08-29 南京明德新药研发有限公司 吗啉取代的苯并嘧啶类化合物的晶型及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN191496B (es) * 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
GB2383042A (en) * 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
CA2678477A1 (en) * 2007-02-16 2008-08-21 Eisai R&D Management Co., Ltd. Crystal, amorphous form and salt of methyl n-[3-(6,7-dimethoxy-2-methylaminoquinazolin-4-yl)phenyl]terephthalamic acid
CN101939009B (zh) * 2008-02-05 2013-07-17 哈博生物科学公司 药学固体形式
IT1404157B1 (it) * 2010-12-30 2013-11-15 Nano Active Film S R L Forma cristallina nanoporosa disordinata di polistirene sindiotattico, suo processo di preparazione e articoli comprendenti la stessa.
DE102013008118A1 (de) 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
SG10201709926VA (en) * 2013-05-30 2017-12-28 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
US10905146B2 (en) * 2013-07-12 2021-02-02 The Coca-Cola Company Compositions for improving rebaudioside M solubility
EP3307722B1 (en) * 2015-06-12 2021-08-04 GB006, Inc. Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid

Also Published As

Publication number Publication date
RU2019133577A3 (es) 2021-07-30
MX2019011649A (es) 2019-12-19
WO2018178133A1 (en) 2018-10-04
ES2956036T3 (es) 2023-12-12
JP7365904B2 (ja) 2023-10-20
IL269667B1 (en) 2024-05-01
IL269667B2 (en) 2024-09-01
IL269667A (en) 2019-11-28
KR20190136037A (ko) 2019-12-09
TW201900634A (zh) 2019-01-01
SG11201909059XA (en) 2019-10-30
CA3058285A1 (en) 2018-10-04
CN110446705B (zh) 2023-04-14
CA3058285C (en) 2024-02-06
ZA201907144B (en) 2023-10-25
EP3601265A1 (en) 2020-02-05
US20200123144A1 (en) 2020-04-23
EP3601265B1 (en) 2023-06-21
AU2018246257A1 (en) 2019-11-14
AU2018246257B2 (en) 2022-05-12
TWI781161B (zh) 2022-10-21
DK3601265T3 (da) 2023-09-18
AU2018246257A8 (en) 2019-11-28
US11053233B2 (en) 2021-07-06
JP2020512362A (ja) 2020-04-23
RU2019133577A (ru) 2021-04-30
CN110446705A (zh) 2019-11-12

Similar Documents

Publication Publication Date Title
CL2019001369A1 (es) Composición farmacéutica para prevenir o tratar el cáncer de mama, incluido el polimorfo cristalino del hexoxido tetraarsenico y el método para producirlo.
CY1123059T1 (el) Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1
PH12017500416A1 (en) Compounds and compositions as raf kinase inhibitors
MX373307B (es) Compuestos de biaril-amida como inhibidores de cinasa.
UY35675A (es) Derivados sustituidos de quinazolin-4-ona
MX377124B (es) Compuestos heterociclicos y usos de los mismos.
MX380777B (es) Compuestos y composiciones como agonistas del receptor tipo toll 7.
UY35663A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
EA201691302A1 (ru) Новые гетероциклические соединения
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
MX2016012103A (es) Agonistas del receptor muscarinico.
MX371050B (es) Compuestos para tratar atrofia muscular espinal.
DOP2015000157A (es) Lactamas fusionadas de arilo y heteroarilo
MX381235B (es) Análogos de éter fosfolipídico como portadores de fármacos dirigidos a cáncer.
MX374513B (es) Compuestos de morfolinona de ácido heteroarilo como inhibidores mdm2 para el tratamiento de cáncer.
GT201300174A (es) Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme)
UY35381A (es) Pirrolotriazinas como inhibidores del canal del ion potasio
EA201692003A1 (ru) Макроциклические производные пиримидина
EA201692000A1 (ru) Макроциклические производные пиридина
MX378732B (es) Formas solidas novedosas
CU20160192A7 (es) Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble
MX2019003026A (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2.
MX2017016619A (es) Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos.
MX394899B (es) Forma solida de (s)-[2-cloro-4-fluoro-5-(7-morfolin-4-il-quinazolin-4-il)fenil]-(6-metoxi-piridazin-3-il)-metanol.
MX382175B (es) Composiciones de profármaco de monometilfumarato